These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18095864)

  • 1. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
    Fan JQ; Ishii S
    FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
    Germain DP; Fan JQ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
    Sawkar AR; Schmitz M; Zimmer KP; Reczek D; Edmunds T; Balch WE; Kelly JW
    ACS Chem Biol; 2006 May; 1(4):235-51. PubMed ID: 17163678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM; Sathe S
    Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological chaperone therapy for lysosomal storage disorders - leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins.
    Fan JQ
    FEBS J; 2007 Oct; 274(19):4943. PubMed ID: 17894778
    [No Abstract]   [Full Text] [Related]  

  • 11. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.
    Sloan LA; Fillmore MC; Churcher I
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):666-81. PubMed ID: 19736625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
    Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32660097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.
    Fan JQ
    Trends Pharmacol Sci; 2003 Jul; 24(7):355-60. PubMed ID: 12871668
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemical and pharmacological chaperones as new therapeutic agents.
    Loo TW; Clarke DM
    Expert Rev Mol Med; 2007 Jun; 9(16):1-18. PubMed ID: 17597553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaucher disease.
    Butters TD
    Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for lysosomal storage disorders.
    Lachmann R
    Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
    Desnick RJ; Schuchman EH
    Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.